Up to $7.5 billion is spent annually on the treatment of burns in the United States, and much of this cost is related to treatment of the resulting scar and contracture (Marshall et al., 2018, PMID: 29392092). Therefore, it is important to develop a therapy that will mitigate the life-long disability and rehabilitation costs associated with these post-injury conditions. The goal of this program is to develop an anti-scar drug, pirfenidone (Pf), for the acute management and prophylactic treatment of deep partial-thickness burn wounds that is conducive to operations in combat theatre as well as fixed medical facilities. The team will develop Pf into a planar dosage form, execute manufacturing, perform studies required for a regulatory filing, and conduct early phase clinical trials of this anti-scarring prototype. MTEC is excited to see this program launch!